Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Vertex hepatitis C drug revenues plummet

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval.

Published
30 January 2013
From
Boston Business Journal (blog)
Hepatitis C progress in pipeline: New drugs to treat virus expected be available in 2014-15

For more on this rapidly changing landscape, we turned to Dr. Donald M. Jensen, director of the Center for Liver Diseases at University of Chicago Medicine and a noted hepatitis C researcher, with more than 100 peer-reviewed articles.

Published
29 January 2013
From
Chicago Tribune
Phase II all-oral combination studies of simeprevir, TMC647055 and IDX719 for the treatment of hepatitis C to be initiated shortly

The collaboration will evaluate combinations including simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once daily NNI (non-nucleoside inhibitor) of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
29 January 2013
From
Medivir press release
Guide to Clinical Trials for People with Hepatitis C

There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you.

Published
18 January 2013
From
Treatment Action Group
Achillion Continues To Make Significant Strides In The Fight Against Hepatitis C

Financial analysis of the Achillion hepatitis C drug pipeline; "Achillion is making considerable strides in terms of four drugs currently in its pipeline," Seeking Alpha comments.

Published
15 January 2013
From
Seeking Alpha
Roche Scientists Uncover Unexpected Enzyme Activity in HCV RNA Polymerase

Today, Roche scientists detail the discovery of a new enzyme activity that allows HCV polymerase to remove nucleosides and nucleoside analogues from RNA molecules. This could lead to HCV polymerase counteracting the activity of nucleoside analogs and result in the development of pathways enabling HCV resistance.

Published
11 January 2013
From
Biospace
Nucleotide Polymerase Inhibitors - The Search For A Safe Interferon Free Trial

While the HCV community is waiting in the wings for the first all interferon-sparing therapy to make its way down the pipeline and hopefully all the way to FDA approval, the search for a clinical trial without interferon has become a reality.

Published
10 January 2013
From
HCV New Drugs Research
Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc. (IDIX), a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

Published
10 January 2013
From
Businessweek
Gilead Provides Update on Hepatitis C Development Programs

Sustained Virologic Response Achieved with Oral Regimen of Sofosbuvir, GS-5885 and Ribavirin in 9/9 Null Responder Genotype 1 Hepatitis C Patients; Second Phase 3 Study Evaluating Fixed-dose Combination of Sofosbuvir and GS-5885 to Begin Later this Month.

Published
08 January 2013
From
Gilead press release
Achillion Reports Interim Results on ACH-3102

Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients; up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.

Published
08 January 2013
From
Achillion press release

Filter by country